Background Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disease caused by GAA repeat expansion in the first intron of the FXN gene, which encodes frataxin, an essential mitochondrial protein. To further characterise the molecular abnormalities associated with FRDA pathogenesis and to hasten drug screening, the development and use of animal and cellular models is considered essential. Studies of lower organisms have already contributed to understanding FRDA disease pathology, but mammalian cells are more related to FRDA patient cells in physiological terms. Methodology/Principal Findings We have generated fibroblast cells and neural stem cells (NSCs) from control Y47R mice (9 GAA repeats) and GAA repeat expansion YG8R mice (190+120 GAA repeats). We then differentiated the NSCs in to neurons, oligodendrocytes and astrocytes as confirmed by immunocytochemical analysis of cell specific markers. The three YG8R mouse cell types (fibroblasts, NSCs and differentiated NSCs) exhibit GAA repeat stability, together with reduced expression of frataxin and reduced aconitase activity compared to control Y47R cells. Furthermore, YG8R cells also show increased sensitivity to oxidative stress and downregulation of Pgc-1α and antioxidant gene expression levels, especially Sod2. We also analysed various DNA mismatch repair (MMR) gene expression levels and found that YG8R cells displayed significant reduction in expression of several MMR genes, which may contribute to the GAA repeat stability. Conclusions/Significance We describe the first fibroblast and NSC models from YG8R FRDA mice and we confirm that the NSCs can be differentiated into neurons and glia. These novel FRDA mouse cell models, which exhibit a FRDA-like cellular and molecular phenotype, will be valuable resources to further study FRDA molecular pathogenesis. They will also provide very useful tools for preclinical testing of frataxin-increasing compounds for FRDA drug therapy, for gene therapy, and as a source of cells for cell therapy testing in FRDA mice.
References
[1]
Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, et al. (1996) Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271: 1423–1427. doi: 10.1126/science.271.5254.1423
[2]
Cossee M, Durr A, Schmitt M, Dahl N, Trouillas P, et al. (1999) Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 45: 200–206. doi: 10.1002/1531-8249(199902)45:2<200::aid-ana10>3.0.co;2-u
[3]
Gellera C, Castellotti B, Mariotti C, Mineri R, Seveso V, et al. (2007) Frataxin gene point mutations in Italian Friedreich ataxia patients. Neurogenetics 8: 289–299. doi: 10.1007/s10048-007-0101-5
[4]
Evans-Galea MV, Corben LA, Hasell J, Galea CA, Fahey MC, et al. (2011) A novel deletion-insertion mutation identified in exon 3 of FXN in two siblings with a severe Friedreich ataxia phenotype. Neurogenetics 12: 307–313. doi: 10.1007/s10048-011-0296-3
[5]
Zuhlke CH, Dalski A, Habeck M, Straube K, Hedrich K, et al. (2004) Extension of the mutation spectrum in Friedreich’s ataxia: detection of an exon deletion and novel missense mutations. Eur J Hum Genet 12: 979–982. doi: 10.1038/sj.ejhg.5201257
[6]
Anheim M, Mariani LL, Calvas P, Cheuret E, Zagnoli F, et al. (2012) Exonic deletions of FXN and early-onset Friedreich ataxia. Arch Neurol 69: 912–916. doi: 10.1001/archneurol.2011.834
[7]
Schols L, Amoiridis G, Przuntek H, Frank G, Epplen JT, et al. (1997) Friedreich’s ataxia. Revision of the phenotype according to molecular genetics. Brain 120 (Pt 12): 2131–2140. doi: 10.1093/brain/120.12.2131
Sharma R, De Biase I, Gomez M, Delatycki MB, Ashizawa T, et al. (2004) Friedreich ataxia in carriers of unstable borderline GAA triplet-repeat alleles. Ann Neurol 56: 898–901. doi: 10.1002/ana.20333
[10]
Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, et al. (1996) Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med 335: 1169–1175. doi: 10.1056/nejm199610173351601
[11]
Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, et al. (1996) The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 59: 554–560.
[12]
Chandok GS, Patel MP, Mirkin SM, Krasilnikova MM (2012) Effects of Friedreich’s ataxia GAA repeats on DNA replication in mammalian cells. Nucleic Acids Res 40: 3964–3974. doi: 10.1093/nar/gks021
[13]
Sakamoto N, Ohshima K, Montermini L, Pandolfo M, Wells RD (2001) Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J Biol Chem 276: 27171–27177. doi: 10.1074/jbc.m101879200
[14]
Ezzatizadeh V, Pinto RM, Sandi C, Sandi M, Al-Mahdawi S, et al. (2012) The mismatch repair system protects against intergenerational GAA repeat instability in a Friedreich ataxia mouse model. Neurobiol Dis 46: 165–171. doi: 10.1016/j.nbd.2012.01.002
[15]
Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, et al. (1997) Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 6: 1771–1780. doi: 10.1093/hmg/6.11.1771
[16]
Pianese L, Turano M, Lo Casale MS, De Biase I, Giacchetti M, et al. (2004) Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J Neurol Neurosurg Psychiatry 75: 1061–1063. doi: 10.1136/jnnp.2003.028605
[17]
Bradley JL, Blake JC, Chamberlain S, Thomas PK, Cooper JM, et al. (2000) Clinical, biochemical and molecular genetic correlations in Friedreich’s ataxia. Hum Mol Genet 9: 275–282. doi: 10.1093/hmg/9.2.275
[18]
Waldvogel D, van Gelderen P, Hallett M (1999) Increased iron in the dentate nucleus of patients with Friedrich’s ataxia. Ann Neurol 46: 123–125. doi: 10.1002/1531-8249(199907)46:1<123::aid-ana19>3.0.co;2-h
[19]
Koeppen AH, Michael SC, Knutson MD, Haile DJ, Qian J, et al. (2007) The dentate nucleus in Friedreich’s ataxia: the role of iron-responsive proteins. Acta Neuropathol 114: 163–173. doi: 10.1007/s00401-007-0220-y
[20]
Foury F, Cazzalini O (1997) Deletion of the yeast homologue of the human gene associated with Friedreich’s ataxia elicits iron accumulation in mitochondria. FEBS Lett 411: 373–377. doi: 10.1016/s0014-5793(97)00734-5
[21]
Wong A, Yang J, Cavadini P, Gellera C, Lonnerdal B, et al. (1999) The Friedreich’s ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet 8: 425–430. doi: 10.1093/hmg/8.3.425
[22]
Schulz JB, Boesch S, Burk K, Durr A, Giunti P, et al. (2009) Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol 5: 222–234. doi: 10.1038/nrneurol.2009.26
[23]
Puccio H (2009) Multicellular models of Friedreich ataxia. J Neurol 256 Suppl 118–24. doi: 10.1007/s00415-009-1004-1
[24]
Perdomini M, Hick A, Puccio H, Pook MA (2013) Animal and cellular models of Friedreich ataxia. J Neurochem 126 Suppl 165–79. doi: 10.1111/jnc.12219
[25]
Tan G, Napoli E, Taroni F, Cortopassi G (2003) Decreased expression of genes involved in sulfur amino acid metabolism in frataxin-deficient cells. Hum Mol Genet 12: 1699–1711. doi: 10.1093/hmg/ddg187
[26]
Sarsero JP, Li L, Wardan H, Sitte K, Williamson R, et al. (2003) Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J Gene Med 5: 72–81. doi: 10.1002/jgm.320
[27]
Grant L, Sun J, Xu H, Subramony SH, Chaires JB, et al. (2006) Rational selection of small molecules that increase transcription through the GAA repeats found in Friedreich’s ataxia. FEBS Lett 580: 5399–5405. doi: 10.1016/j.febslet.2006.09.006
[28]
Lufino MM, Silva AM, Nemeth AH, Alegre-Abarrategui J, Russell AJ, et al. (2013) A GAA repeat expansion reporter model of Friedreich’s ataxia recapitulates the genomic context and allows rapid screening of therapeutic compounds. Hum Mol Genet 22: 5173–5187. doi: 10.1093/hmg/ddt370
[29]
Calmels N, Schmucker S, Wattenhofer-Donze M, Martelli A, Vaucamps N, et al. (2009) The first cellular models based on frataxin missense mutations that reproduce spontaneously the defects associated with Friedreich ataxia. PLoS ONE 4: e6379. doi: 10.1371/journal.pone.0006379
[30]
Ku S, Soragni E, Campau E, Thomas EA, Altun G, et al. (2010) Friedreich’s Ataxia Induced Pluripotent Stem Cells Model Intergenerational GAATTC Triplet Repeat Instability. Cell Stem Cell 7: 631–637. doi: 10.1016/j.stem.2010.09.014
[31]
Liu J, Verma PJ, Evans-Galea MV, Delatycki MB, Michalska A, et al. (2011) Generation of induced pluripotent stem cell lines from Friedreich ataxia patients. Stem Cell Rev 7: 703–713. doi: 10.1007/s12015-010-9210-x
[32]
Hick A, Wattenhofer-Donze M, Chintawar S, Tropel P, Simard JP, et al. (2013) Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich’s ataxia. Dis Model Mech 6: 608–621.
[33]
Pook MA, Al-Mahdawi S, Carroll CJ, Cossee M, Puccio H, et al. (2001) Rescue of the Friedreich’s ataxia knockout mouse by human YAC transgenesis. Neurogenetics 3: 185–193.
[34]
Al-Mahdawi S, Pinto RM, Varshney D, Lawrence L, Lowrie MB, et al. (2006) GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 88: 580–590. doi: 10.1016/j.ygeno.2006.06.015
[35]
De Biase I, Chutake YK, Rindler PM, Bidichandani SI (2009) Epigenetic Silencing in Friedreich Ataxia Is Associated with Depletion of CTCF (CCCTC-Binding Factor) and Antisense Transcription. PLoS ONE 4: e7914. doi: 10.1371/journal.pone.0007914
[36]
Willis JH, Isaya G, Gakh O, Capaldi RA, Marusich MF (2008) Lateral-flow immunoassay for the frataxin protein in Friedreich’s ataxia patients and carriers. Mol Genet Metab 94: 491–497. doi: 10.1016/j.ymgme.2008.03.019
[37]
Holemon H, Korshunova Y, Ordway JM, Bedell JA, Citek RW, et al. (2007) MethylScreen: DNA methylation density monitoring using quantitative PCR. Biotechniques 43: 683–693. doi: 10.2144/000112597
[38]
Al-Mahdawi S, Sandi C, Mouro Pinto R, Pook MA (2013) Friedreich Ataxia Patient Tissues Exhibit Increased 5-Hydroxymethylcytosine Modification and Decreased CTCF Binding at the FXN Locus. PLoS One 8: e74956. doi: 10.1371/journal.pone.0074956
[39]
Levison SW, Druckman SK, Young GM, Basu A (2003) Neural stem cells in the subventricular zone are a source of astrocytes and oligodendrocytes, but not microglia. Dev Neurosci 25: 184–196. doi: 10.1159/000072267
[40]
Montermini L, Andermann E, Labuda M, Richter A, Pandolfo M, et al. (1997) The Friedreich ataxia GAA triplet repeat: premutation and normal alleles. Hum Mol Genet 6: 1261–1266. doi: 10.1093/hmg/6.8.1261
[41]
De Biase I, Rasmussen A, Endres D, Al-Mahdawi S, Monticelli A, et al. (2007) Progressive GAA expansions in dorsal root ganglia of Friedreich’s ataxia patients. Ann Neurol 61: 55–60. doi: 10.1002/ana.21052
Chung DW, Rudnicki DD, Yu L, Margolis RL (2011) A natural antisense transcript at the Huntington’s disease repeat locus regulates HTT expression. Hum Mol Genet 20: 3467–3477. doi: 10.1093/hmg/ddr263
[44]
Khalil AM, Faghihi MA, Modarresi F, Brothers SP, Wahlestedt C (2008) A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. PLoS One 3: e1486. doi: 10.1371/journal.pone.0001486
[45]
Ladd PD, Smith LE, Rabaia NA, Moore JM, Georges SA, et al. (2007) An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet 16: 3174–3187. doi: 10.1093/hmg/ddm293
[46]
Sopher BL, Ladd PD, Pineda VV, Libby RT, Sunkin SM, et al. (2011) CTCF regulates ataxin-7 expression through promotion of a convergently transcribed, antisense noncoding RNA. Neuron 70: 1071–1084. doi: 10.1016/j.neuron.2011.05.027
[47]
Moseley ML, Zu T, Ikeda Y, Gao W, Mosemiller AK, et al. (2006) Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat Genet 38: 758–769. doi: 10.1038/ng1827
[48]
Cho DH, Thienes CP, Mahoney SE, Analau E, Filippova GN, et al. (2005) Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell 20: 483–489. doi: 10.1016/j.molcel.2005.09.002
[49]
Greene E, Mahishi L, Entezam A, Kumari D, Usdin K (2007) Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res 35: 3383–3390. doi: 10.1093/nar/gkm271
[50]
Al-Mahdawi S, Pinto RM, Ismail O, Varshney D, Lymperi S, et al. (2008) The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 17: 735–746. doi: 10.1093/hmg/ddm346
[51]
Sandi C, Al-Mahdawi S, Pook MA (2013) Epigenetics in Friedreich’s Ataxia: Challenges and Opportunities for Therapy. Genet Res Int 2013: 852080. doi: 10.1155/2013/852080
[52]
Rotig A, de Lonlay P, Chretien D, Foury F, Koenig M, et al. (1997) Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 17: 215–217. doi: 10.1038/ng1097-215
[53]
Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, et al. (2001) Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27: 181–186.
[54]
Coppola G, Marmolino D, Lu D, Wang Q, Cnop M, et al. (2009) Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich’s ataxia. Hum Mol Genet 18: 2452–2461. doi: 10.1093/hmg/ddp183
[55]
Marmolino D, Manto M, Acquaviva F, Vergara P, Ravella A, et al. (2010) PGC-1alpha down-regulation affects the antioxidant response in Friedreich’s ataxia. PLoS One 5: e10025. doi: 10.1371/journal.pone.0010025
[56]
Marmolino D, Acquaviva F, Pinelli M, Monticelli A, Castaldo I, et al. (2009) PPAR-gamma agonist Azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich’s ataxia therapy. Cerebellum 8: 98–103. doi: 10.1007/s12311-008-0087-z
[57]
Shan Y, Schoenfeld RA, Hayashi G, Napoli E, Akiyama T, et al. (2013) Frataxin Deficiency Leads to Defects in Expression of Antioxidants and Nrf2 Expression in Dorsal Root Ganglia of the Friedreich’s Ataxia YG8R Mouse Model. Antioxid Redox Signal 19: 1481–1493. doi: 10.1089/ars.2012.4537
[58]
Geng T, Li P, Okutsu M, Yin X, Kwek J, et al. (2010) PGC-1alpha plays a functional role in exercise-induced mitochondrial biogenesis and angiogenesis but not fiber-type transformation in mouse skeletal muscle. Am J Physiol Cell Physiol 298: C572–579. doi: 10.1152/ajpcell.00481.2009
[59]
St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, et al. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127: 397–408. doi: 10.1016/j.cell.2006.09.024
[60]
García-Giménez JL, Gimeno A, Gonzalez-Cabo P, Dasí F, Bolinches-Amorós A, et al. (2011) Differential Expression of PGC-1α and Metabolic Sensors Suggest Age-Dependent Induction of Mitochondrial Biogenesis in Friedreich Ataxia Fibroblasts. PLoS ONE 6: e20666. doi: 10.1371/journal.pone.0020666
[61]
Halabi A, Ditch S, Wang J, Grabczyk E (2012) DNA mismatch repair complex MutSbeta promotes GAA.TTC repeat expansion in human cells. J Biol Chem 287: 29958–29967. doi: 10.1074/jbc.m112.356758
[62]
Bourn RL, De Biase I, Pinto RM, Sandi C, Al-Mahdawi S, et al. (2012) Pms2 suppresses large expansions of the (GAA.TTC)n sequence in neuronal tissues. PLoS One 7: e47085. doi: 10.1371/journal.pone.0047085
[63]
Clark RM, De Biase I, Malykhina AP, Al-Mahdawi S, Pook M, et al. (2007) The GAA triplet-repeat is unstable in the context of the human FXN locus and displays age-dependent expansions in cerebellum and DRG in a transgenic mouse model. Hum Genet 120: 633–640. doi: 10.1007/s00439-006-0249-3
[64]
Du J, Campau E, Soragni E, Ku S, Puckett JW, et al. (2012) Role of mismatch repair enzymes in GAA.TTC triplet-repeat expansion in Friedreich ataxia induced pluripotent stem cells. J Biol Chem 287: 29861–29872. doi: 10.1074/jbc.m112.391961
[65]
Evans-Galea MV, Carrodus N, Rowley SM, Corben LA, Tai G, et al. (2012) FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann Neurol 71: 487–497. doi: 10.1002/ana.22671
[66]
Castaldo I, Pinelli M, Monticelli A, Acquaviva F, Giacchetti M, et al. (2008) DNA methylation in intron 1 of the frataxin gene is related to GAA repeat length and age of onset in Friedreich ataxia patients. J Med Genet 45: 808–812. doi: 10.1136/jmg.2008.058594
[67]
Vaubel RA, Isaya G (2013) Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia. Mol Cell Neurosci 55: 50–61. doi: 10.1016/j.mcn.2012.08.003
[68]
Van Remmen H, Ikeno Y, Hamilton M, Pahlavani M, Wolf N, et al. (2003) Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol Genomics 16: 29–37. doi: 10.1152/physiolgenomics.00122.2003
[69]
Heidari MM, Houshmand M, Hosseinkhani S, Nafissi S, Khatami M (2009) Complex I and ATP content deficiency in lymphocytes from Friedreich’s ataxia. Can J Neurol Sci 36: 26–31.
[70]
Bulteau AL, O’Neill HA, Kennedy MC, Ikeda-Saito M, Isaya G, et al. (2004) Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 305: 242–245. doi: 10.1126/science.1098991
